<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A phase II trial was conducted to explore the efficacy and tolerability of combining thalidomide (100 mg/d p.o.) with an erythropoietic growth factor (darbepoietin-alpha 2.25 micro g/kg/d s.c.) in patients with low-to-intermediate-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the trial had to be discontinued early because of an unexpectedly high incidence of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Of the first seven patients enrolled, two developed <z:hpo ids='HP_0002625'>deep-vein thrombosis</z:hpo> and one died of massive <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We concluded that thalidomide might significantly increase the thromboembolic risk of erythropoietic proteins in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Careful clinical surveillance and <z:mp ids='MP_0005048'>thrombosis</z:mp> prophylaxis (<z:chebi fb="5" ids="28304">heparin</z:chebi> or oral anticoagulation) should be considered for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients undergoing combined treatment with thalidomide and erythropoietic growth factors </plain></SENT>
</text></document>